6Lacourciere Y, Lehis J, R Omhard, et al. A comparison of thee cacies and duration of action of the angiotensin Ⅱ receptor blockers telmis- artan and amledipine [ J ]. Blood Press Monit, 1998,3:295-302.
7Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:the JNC7 report[ J]. JAMA, 2003 ;289:2560-2571.
9Marino Mr, Langenvacher K, Ford NF, et al. Pharmacokinetics and pharmaeodynamics of Irbesartan in health subjects[J]. J Clin Phar- maeol, 1998,38:246-255.
2Culleton BF , larson MG, Kannel WB , et al. Serum uric acid and risk for cardiovascular disease and death : the Framingham Heart study[J] . Ann Intern Med ,1999 ;131(1)∶7 - 13.
3Elisaf M, Tsimichodimos V,Bairaktari E , et al. Effect of Mrcronizde fenoflbrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia [J]. Cardiovasc pharmacol,1999,34(1)∶60-63.
4Alderman MH,Cohen H,Madhavan S,et al.Serum uric acid and cardiovascular events in successfully treated hypertersive patients[J].hypertension,1993,34(1)∶144-150.
5SICA DA,SCHOOL WERTH AC.Uric acid and losartan[J].Curr Opin Nephrol Hypertens,2002,11(5)∶475-482.
6Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 2004, 363: 2022-2031.
7Hasford J, Mimran A, Simons WR. A population-based european cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens, 2002, 16: 569-575.
8Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther, 1998, 20: 671-681.
9Elliott WJ. Cyclic and circadian variations in cardiovascular events. Am J Hypertens, 2001, S291-S295.
10Shimada K, Kawamoto A, Matsubayashi K, et al. Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension. J Hypertens, 1992, 10: 875-878.
6Elisaf M, Tsimichodimos V, Bairaktari E, et al. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia[J]. J Cardiovasc Pharmacol, 1999, 34(1): 60-63.
7Wahren J, Ekberg K, JiSmvall H. C-peptide is a bioactive peptide[J]. Diabetologia, 2007, 50(3): 503-509.
8Berthoux Fc, Mohey H, Afiani A. Natural history of primary IgA nephropathy[ J] .Semin Nephro1,2008,28( 1 ) :4-9.
